DENTSPLY SIRONA (NASDAQ:XRAY) Issues Earnings Results

DENTSPLY SIRONA (NASDAQ:XRAY) released its quarterly earnings results on Thursday. The medical instruments supplier reported $0.52 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.35 by $0.17, FiscalAI reports. The firm had revenue of $898.00 million for the quarter, compared to the consensus estimate of $889.93 million. DENTSPLY SIRONA had a positive return on equity of 18.83% and a negative net margin of 17.06%.The company’s revenue for the quarter was down 4.1% on a year-over-year basis. During the same quarter last year, the business posted $0.52 EPS. DENTSPLY SIRONA updated its FY 2026 guidance to 1.400-1.500 EPS.

Here are the key takeaways from DENTSPLY SIRONA’s conference call:

• Q2 revenue declined: Sales fell 4.1% as reported, or 6.3% on a constant-currency basis, with weakness in CAD/CAM, dental consumables, implants and SureSmile. Adjusted EPS was flat at $0.52, while adjusted EBITDA margins were roughly unchanged only after a $44 million tariff refund.
• DENTSPLY SIRONA maintained its 2026 outlook for revenue of $3.5 billion–$3.6 billion and adjusted EPS of $1.40–$1.50, excluding tariff-related effects. Management expects Q3 revenue and earnings to decline sequentially because of seasonality and planned investments.
• The company said the U.S. recovery remains its top priority, but commercial-force training and dealer expansion are expected to have a larger impact in 2027 rather than this year. Management also acknowledged that the U.S. is currently lagging competitors in implants and that SureSmile remains pressured.
• Management reported progress on its 24-month Return-to-Growth plan, including expanded dealer partnerships, clinical education, sales-force certification and increased R&D investment, with improvements expected to become more visible in Q4. DS Core adoption and double-digit APAC milling-system growth were cited as encouraging signs.
• Wellspect remained a bright spot, with revenue up 7.1% on continued new-product sales and geographic expansion. Operating cash flow rose to $99 million from $48 million, and the company repurchased 1.3 million shares while continuing to prioritize debt reduction.

DENTSPLY SIRONA Stock Down 4.4%

Shares of XRAY opened at $13.17 on Friday. The company has a current ratio of 1.53, a quick ratio of 0.98 and a debt-to-equity ratio of 1.52. DENTSPLY SIRONA has a 12 month low of $9.40 and a 12 month high of $14.86. The firm’s 50 day moving average is $11.74 and its 200-day moving average is $11.89. The stock has a market capitalization of $2.64 billion, a PE ratio of -4.18, a P/E/G ratio of 1.64 and a beta of 0.85.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on XRAY shares. Citigroup began coverage on DENTSPLY SIRONA in a report on Wednesday, April 15th. They set a “sell” rating and a $10.00 price objective for the company. Barclays cut their target price on DENTSPLY SIRONA from $12.00 to $9.00 and set an “underweight” rating on the stock in a research note on Thursday, June 4th. Mizuho reduced their price target on DENTSPLY SIRONA from $16.00 to $14.00 and set a “neutral” rating for the company in a research report on Wednesday, May 6th. UBS Group decreased their price target on shares of DENTSPLY SIRONA from $18.00 to $17.00 and set a “buy” rating for the company in a research note on Thursday, May 7th. Finally, Piper Sandler lifted their price objective on shares of DENTSPLY SIRONA from $13.00 to $14.00 and gave the company a “neutral” rating in a report on Wednesday, July 29th. Three equities research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $13.46.

Insider Buying and Selling at DENTSPLY SIRONA

In related news, Director Brian T. Gladden purchased 9,985 shares of the firm’s stock in a transaction that occurred on Monday, June 15th. The shares were bought at an average price of $10.02 per share, for a total transaction of $100,049.70. Following the completion of the transaction, the director owned 61,849 shares of the company’s stock, valued at approximately $619,726.98. This trade represents a 19.25% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this link. Also, Director Brian P. Mckeon purchased 10,000 shares of the company’s stock in a transaction that occurred on Friday, June 12th. The stock was bought at an average cost of $10.12 per share, with a total value of $101,200.00. Following the purchase, the director owned 10,000 shares of the company’s stock, valued at $101,200. This represents a ∞ increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders purchased 35,160 shares of company stock valued at $351,179 in the last three months. Corporate insiders own 0.46% of the company’s stock.

Institutional Investors Weigh In On DENTSPLY SIRONA

A number of large investors have recently bought and sold shares of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in shares of DENTSPLY SIRONA during the 1st quarter worth approximately $26,000. Goldman Sachs Group Inc. increased its stake in DENTSPLY SIRONA by 827.3% in the first quarter. Goldman Sachs Group Inc. now owns 2,434,925 shares of the medical instruments supplier’s stock valued at $36,378,000 after acquiring an additional 2,172,343 shares during the last quarter. Empowered Funds LLC increased its stake in DENTSPLY SIRONA by 8.8% in the first quarter. Empowered Funds LLC now owns 16,324 shares of the medical instruments supplier’s stock valued at $244,000 after acquiring an additional 1,320 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in DENTSPLY SIRONA by 7.5% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 593,021 shares of the medical instruments supplier’s stock valued at $8,860,000 after purchasing an additional 41,579 shares in the last quarter. Finally, Focus Partners Wealth raised its position in DENTSPLY SIRONA by 59.1% during the first quarter. Focus Partners Wealth now owns 25,181 shares of the medical instruments supplier’s stock valued at $376,000 after purchasing an additional 9,355 shares in the last quarter. 95.70% of the stock is currently owned by institutional investors and hedge funds.

DENTSPLY SIRONA Company Profile

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.